Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 16.48M
June 30, 2026 20.58M
March 31, 2026 22.76M
December 31, 2025 27.24M
September 30, 2025 33.80M
June 30, 2025 40.90M
March 31, 2025 48.73M
December 31, 2024 55.69M
September 30, 2024 60.22M
June 30, 2024 61.36M
March 31, 2024 60.84M
December 31, 2023 58.21M
September 30, 2023 58.06M
Date Value
June 30, 2023 61.42M
March 31, 2023 64.81M
December 31, 2022 68.23M
September 30, 2022 74.13M
June 30, 2022 74.55M
March 31, 2022 75.52M
December 31, 2021 71.98M
September 30, 2021 64.51M
June 30, 2021 55.13M
March 31, 2021 44.92M
December 31, 2020 37.85M
September 30, 2020 30.68M
June 30, 2020 27.58M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Caribou Biosciences, Inc. 84.72M
Oncolytics Biotech, Inc. 13.18M
Sangamo Therapeutics, Inc. 113.79M
Sarepta Therapeutics, Inc. 647.26M
Anixa Biosciences, Inc. 4.828M